読み込み中
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
終値時点
$1.44
+$0.05 · +3.60%
時間外
$1.46
+$0.02 · +1.39%
10月8日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
日中レンジ
現在 $1.44
52週レンジ
現在 $1.44
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
33
割高
センチメント
75
強気
リスク
59
やや高いリスク
モメンタム
88
強い上昇
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
日中レンジ
現在 $1.44
52週レンジ
現在 $1.44
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 4109.5万 USD | 3608.4万 USD | 1575.9万 USD | — |
| 売上原価 | 11.6万 USD | — | — | — | — |
| 粗利益 | −11.6万 USD | 4109.5万 USD | 3608.4万 USD | 1575.9万 USD | — |
| 研究開発 | 1284.3万 USD | 3742.8万 USD | 3703.9万 USD | 3754.7万 USD | 2637.9万 USD |
| 販売・一般管理 | 1079.1万 USD | 1193.6万 USD | 1356.7万 USD | 1723.9万 USD | 1140.7万 USD |
| 営業費用 | 2363.4万 USD | 4936.4万 USD | 5060.6万 USD | 7783.5万 USD | 3778.6万 USD |
| 受取利息 | 83.3万 USD | 138.1万 USD | 233.4万 USD | 42万 USD | 5.7万 USD |
| 支払利息 | — | — | 49.1万 USD | 105.3万 USD | 107.3万 USD |
| 減価償却費と償却費 | 11.6万 USD | 13.7万 USD | 12.6万 USD | 11.8万 USD | 7.2万 USD |
| 営業利益 | −2363.4万 USD | −826.9万 USD | −1452.2万 USD | −6207.6万 USD | −3778.6万 USD |
| 純利益 | −2239.8万 USD | −806.7万 USD | −1333.5万 USD | −6242.8万 USD | −3898万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$6.25
上昇余地（334.03%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI318.24万0.00%2.3兆 USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF84.75万0.00%954億 USD0.05%$233.13-0.15%
iShares Micro-Cap ETFIWC20.29万0.02%13.33億 USD0.60%$182.79-0.31%
Avantis U.S. Small Cap Equity ETFAVSC10.48万—30.38億 USD0.25%$69.96+0.47%
Invesco NASDAQ Future Gen 200 ETFQQQS7.3万0.32%2296.09万 USD0.20%$41.5683-1.09%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCInvesco NASDAQ Future Gen 200 ETFQQQSAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
